1-5 of 5
Alan F. List
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia

Anthony M. Hunter, Hannah Newman, Amy E. Dezern, David P. Steensma, Sandrine Niyongere, Gail J. Roboz, Qianxing Mo, Onyee Chan, Aaron Gerds, David A. Sallman, William Dominguez-Viqueira, Christopher Letson, Maria E. Balasis, Markus Ball, Traci Kruer, Hailing Zhang, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, Rami S. Komrokji, Eric Padron
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6095–6105.
https://doi.org/10.1158/1078-0432.CCR-21-0935
Published: 15 November 2021
View article titled, Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Open the PDF for Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

Kendra Sweet, Rami Komrokji, Eric Padron, Christopher L. Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Julio Chavez, Bijal D. Shah, Jeffrey E. Lancet
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 54–60.
https://doi.org/10.1158/1078-0432.CCR-19-2169
Published: 03 January 2020
View article titled, Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Open the PDF for Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks

Sriram Sundaravel, Wen-Liang Kuo, Jong Jin Jeong, Gaurav S. Choudhary, Shanisha Gordon-Mitchell, Hui Liu, Tushar D. Bhagat, Kathy L. McGraw, Sandeep Gurbuxani, Alan F. List, Amit Verma, Amittha Wickrema
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5638–5649.
https://doi.org/10.1158/1078-0432.CCR-19-0924
Published: 13 September 2019
View article titled, Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks
Open the PDF for Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks in another window
Includes: Supplementary data
Journal Articles

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)

Eric Padron, Amy Dezern, Marcio Andrade-Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E. Balasis, Sara Tinsley, Hanadi Ramadan, Cassandra Zimmerman, David P. Steensma, Gail J. Roboz, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, Rami S. Komrokji
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (15): 3746–3754.
https://doi.org/10.1158/1078-0432.CCR-15-2781
Published: 31 July 2016
View article titled, A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML)
Open the PDF for A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) in another window
Includes: Supplementary data
Journal Articles

Selective Exclusion by the Polyamine Transporter as a Mechanism for Differential Radioprotection of Amifostine Derivatives

Herson I. Quiñones, Alan F. List, Eugene W. Gerner
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 1295–1300.
Published: 01 May 2002
View article titled, Selective Exclusion by the Polyamine Transporter as a Mechanism for Differential Radioprotection of Amifostine Derivatives
Open the PDF for Selective Exclusion by the Polyamine Transporter as a Mechanism for Differential Radioprotection of Amifostine Derivatives in another window